Скачать или смотреть Treatment algorithm for low-risk MDS

Valeria Santini, MD, University of Florence, Florence, Italy, discusses the treatment algorithm of low-risk myelodysplastic syndrome (MDS) as well as the importance of genetic understanding of disease to guide treatment, including treating del5q mutated patients with lenalidomide as well as the significance of TP53 mutations. Prof. Santini also discusses the approval of luspatercept for the treatment of anemia in lower-risk MDS, as well as roxadustat, an oral HIF prolyl-hydroxylase inhibitor currently being evaluated in lower-risk MDS with anemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).